Complications after BCG immunotherapy – neither a mountain nor a molehill

Re: Bladder health in patients treated with BCG instillations for T1G2-G3 bladder cancer – a follow-up five years after the start of treatment

Wojciech KrajewskiDepartment of Urology and Oncological Urology, Wrocław Medical University, Wrocław, PolandCorrespondence[email protected]

Sławomir PoletajewDepartment of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland

Romuald ZdrojowyDepartment of Urology and Oncological Urology, Wrocław Medical University, Wrocław, Poland

Anna KołodziejDepartment of Urology and Oncological Urology, Wrocław Medical University, Wrocław, Poland

References

Danielsson G, Malmstrom PU, Jahnson S, et al. Bladder health in patients treated with BCG instillations for T1G2-G3 bladder cancer - a follow-up five years after the start of treatment. Scand J Urol. 2018;52:377–384.
PubMed Web of Science ®Google Scholar
Brausi M, Oddens J, Sylvester R, et al. Side effects of Bacillus Calmette-Guerin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. Eur Urol. 2014;65:69–76.
PubMed Web of Science ®Google Scholar
Krajewski W, Matuszewski M, Poletajew S, et al. Are there differences in toxicity and efficacy between various bacillus calmette-guerin strains in bladder cancer patients? Analysis of 844 patients. Urol Int. 2018;101:277–284.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Complications after BCG immunotherapy – neither a mountain nor a molehill

Re: Bladder health in patients treated with BCG instillations for T1G2-G3 bladder cancer – a follow-up five years after the start of treatment

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Complications after BCG immunotherapy – neither a mountain nor a molehill

Re: Bladder health in patients treated with BCG instillations for T1G2-G3 bladder cancer – a follow-up five years after the start of treatment

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date